A 72 -week study compared the safety and effectiveness of injectable weight loss drugs in an attempt to detect the most effective drug in this regard. Trepbound and Monjaro, was the most effective in losing weight in obesity compared to the medicine of Simiglotide, which carries the two commercial names “Wegov” and “OzemPIC”.
The study was led by a researcher from the Will Cornell Medical College and New York Brisbetrayan, conducted in cooperation with the University of Texas McGaven Medical College, the Faculty of Medicine David Given at the University of California Plos Angeles in the United States, the Dublin University College in Ireland, and Eli Lily. Its results were published on May 11 in the “New England Journal of Medicine”, and was written by Yurrick Alert.
Weight challenge and waist
Participants who consumed Terzopatid lost 20.2% of their bodies, while they lost a seedlotide on average 13.7% of their basic weight.
The results of the study showed that when both medicines were given with their maximum doses, the participants who took the Terzopatid medication were more able to reach the weight they wanted and witnessed a greater decrease in the waist circumference than those who take Simiglotide.
Dr. Louis Aaron, director of the Comprehensive Weight Control Center, professor of metabolism at Sanford I Weel at the Will Cornell Medical College and the study researcher, stated that the best performance of the Terzopatid is likely to be linked to the mechanism of the double Terzopatid work.
While Semiglotide works by stimulating hormone receptors called the glucagon-like peptide 1, or GLP-1 (GLP-1), the Terzopatid not only simulates “GLB -1”, but also simulates an additional hormone is an insulin-glucose-based infetty (GIP) (Glucose-Dependent Insulinotropic Peptide (GIP)).
These procedures combined reduce the feeling of hunger, reduce glucose levels in the blood, and affect the metabolism of fatty cells. Aaron said, “Weights are very complicated,” Aaron said.
Directly
Experiments are currently being conducted to determine whether the Terzopatide, such as Simiglotide, also reduces the risk of cardiovascular disease, such as heart attacks and strokes.
The benefit of this study lies in the possibility of comparing medications directly. “Doctors, insurance companies and patients are always wondering: What medication is more effective? This study has allowed us to conduct a direct comparison,” says Aaron, who is also a mystical physician who specializes in diabetes and obesity at the New York-Prisperian/Will Cornell Medical Center.
Elie Lily, the producing company of Terzopatid, has made the study conducted at 32 locations across the United States and Puerto Rico. All participants received consultations on diet and exercise, and the side effects associated with both medicines were very similar. For example, about 44% of individuals in each therapeutic group suffered from nausea, and 25% of abdominal pain.
Aaron and his colleagues are currently conducting tests on the next generation of weight loss drugs, including compounds such as “Retatrutide” from Elie Lily and called “Triple G” (3G) due to the simulation of the three hormones that “GLB1”, “GIP” and glucagon.